An observational study in Thalassemia Particularly Transfusion Dependent Thalassemia, sponsored by Randa Elham Hamam. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Randa Elham Hamam · Observational
This study aims to assess the clinical, economic, and psychosocial burden of thalassemia among affected children in Sohag. Clinically, the study will evaluate disease severity, transfusion requirements, iron overload, complications, and treatment-related factors. Economically, it will estimate direct medical costs, including transfusions, medications, investigations, hospital visits, and other healthcare expenses, as well as indirect costs such as school/work absenteeism and caregiver burden. Psychosocial aspects will include assessment of quality of life, psychological well-being, social functioning, and the impact of the disease on patients and their families.
Thalassemia constitutes one of the most common inherited hemoglobin disorders worldwide and remains a major public health problem in Egypt, where carrier rates approach 9-10% and both alpha and beta thalassemia gene defects are well documented in the population . In Egypt, the burden of disease is particularly evident among pediatric patients with transfusion dependent beta thalassemia (TDT), who require lifelong regular blood transfusions and iron chelation therapy and are consequently at risk of iron overload, organ damage, and transfusion transmitted infections despite improvements in transfusion safety .
Regional studies from Upper Egypt have documented a high frequency of transfusion related complications in multitransfused children, including elevated rates of hepatitis C and other infections, and have highlighted ongoing gaps in screening and blood safety practices that continue to contribute to clinical morbidity . Concurrently, quality of life (QoL) research in Egyptian pediatric thalassemia populations demonstrates consistent and clinically meaningful impairments across physical, emotional, social, and school functioning domains, with socioeconomic disadvantage and markers of greater disease severity (for example, higher ferritin and longer disease duration) associated with worse outcomes .
Beyond direct clinical consequences, thalassemia imposes a substantial economic and psychosocial burden on families and health systems . Cost analyses and health resource studies indicate significant direct medical expenses and large indirect costs from caregiver absenteeism, transport, and lost productivity, and these burdens are magnified in low resource settings where comprehensive social support is limited. Cultural factors such as high rates of consanguineous marriage and variable uptake of premarital screening in Egypt also influence disease prevalence and complicate prevention strategies
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
This study's planned enrollment of 100 is close to the median of 106 across 70 observational studies indexed under Thalassemia.
Browse Thalassemia studies →This is the only study on the registry with Randa Elham Hamam as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study will include children and adolescents diagnosed with thalassemia who are attending pediatric hematology clinics of Sohag University Hospitals for regular follow-up, blood transfusion, or chelation therapy.
Inclusion Criteria: Children and adolescents diagnosed with thalassemia. Age from 2 to 18 years. Regular follow-up at the selected pediatric hematology clinic or thalassemia unit
Exclusion Criteria:Children with other chronic hematological disorders unrelated to thalassemia.
Children with severe acute illness at the time of data collection. Children or caregivers who refuse participation.
-
No experimental intervention data Will be collected from routine clinical care ,medical records,and follow up visits
Clinical burden of thalassemia
Clinical burden will be assessed using the frequency of hospital admissions, blood transfusion requirements, and disease-related complications among children and adolescents with thalassemia.
Time frame: through study completion, an average of 1 year
Economic burden of thalassemia
Economic burden will be assessed based on direct medical costs, including costs of medications, blood transfusions, laboratory investigations, hospitalizations, and other healthcare utilization.
Time frame: through study completion, an average of 1 year
Psychosocial burden of thalassemia
Psychosocial burden will be assessed using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales (PedsQL 4.0), Family APGAR questionnaire, and Patient Health Questionnaire-4 (PHQ-4). The PedsQL 4.0 consists of 23 items and is scored on a 0-100 scale, with higher scores indicating better health-related quality of life. The Family APGAR consists of 5 items with a total score ranging from 0 to 10, with higher scores indicating better family functioning. The PHQ-4 consists of 4 items with a total score ranging from 0 to 12, with higher scores indicating greater psychological distress. The GAD-2 and PHQ-2 subscale scores each range from 0 to 6, with higher scores indicating greater anxiety and depressive symptoms, respectively.
Time frame: through study completion, an average of 1 year
No study locations are listed for this record.
Plan to share: No — Individuals participant data will not be shared due to patients privacy and data protection policies at Sohag university hospital
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.